Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS Press Releases

  • Antibiotic-resistant gonorrhoea on the rise; need for new drugs
  • Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to develop a new treatment for drug-resistant gonorrhea
  • Clinical trial for a better treatment for mycetoma starts in Sudan
  • New open source project engages universities in neglected diseases drug discovery
  • Merck joins DNDi’s ‘Drug Discovery Booster’ to accelerate discovery of new treatments for neglected diseases

RSS In the Media

  • Huffington Post: “A blinding disease destroyed her marriage. Now she says she has nothing”
  • New York Times: “Escaping big pharma’s pricing with patent-free drugs”
  • Business Daily: “Neglected diseases that wreak havoc on northern Kenya”
  • El Pais: “Cinco recetas para la salud global”
  • El Pais: “Apoyo incondicional a los innovadores de la salud”

RSS Scientific Articles

  • Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial
  • Safety and efficacy of short course combination regimens with AmBisome®, miltefosine, paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
  • IFN-g, IL-2, IP-10, and MIG as biomarkers of exposure to leishmania spp., and of cure in human visceral leishmaniasis
  • 7 substituted 2 Nitro-5,6-dihydroimidazo[2,1 b][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis
  • Infectivity of post-kala-azar dermal leishmaniasis patients to sand flies: revisiting a proof of concept in the context of the kala-azar elimination program in the Indian subcontinent

RSS News

  • GARDP at one: R&D programmes getting underway
  • GHIT Fund reinforces its support to DNDi leishmaniasis and Chagas disease projects
  • R&D Status February 2017: DNDi Sleeping sickness programme
  • R&D Status February 2017: DNDi Leishmaniasis programme
  • R&D Status February 2017: DNDi Chagas disease programme

RSS Events

  • Geneva Health Forum
  • ASTMH 2017
  • AASLD The Liver Meeting®
  • ECTMIH 2017
  • International Workshop on Onchocerciasis-associated Epilepsy (OAE)

RSS Scientific Articles

  • Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial
  • Safety and efficacy of short course combination regimens with AmBisome®, miltefosine, paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
  • IFN-g, IL-2, IP-10, and MIG as biomarkers of exposure to leishmania spp., and of cure in human visceral leishmaniasis
  • 7 substituted 2 Nitro-5,6-dihydroimidazo[2,1 b][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

 

Subscribe

Sign up for the E-news newsletter

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

  • TERMS OF USE
  • PRIVACY POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License